Clinical trial

Neoadjuvant Pembrolizumab

NCT02818920

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-01

PhasePHASE2

Study timeline

Study start (actual)2017-01-01Date precision: month

Registry last updated2026-03-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Carcinomaunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Neal Ready MD PhDlead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

DurhamNorth Carolina, United States1 RochesterMinnesota, United States1 LebanonNew Hampshire, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02818920 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.